Why Is Intuitive Surgical Stock Falling in Pre-Market Trading?
Intuitive Surgical (NASDAQ:ISRG) shares declined 7.5% to $404.99 in pre-market trading on Wednesday following the medical technology company’s third-quarter 2026 earnings report. Although adjusted earnings and revenue exceeded analyst expectations, investors were assessing a $450 million legal settlement charge and planned reductions in pricing for certain surgical instruments and accessories.
The decline extended losses recorded in after-hours trading following the earnings announcement, with attention focused on the potential implications of the company’s pricing strategy for future revenue growth.
Did Intuitive Surgical Beat Third-Quarter Earnings Expectations?
Intuitive Surgical reported third-quarter non-GAAP earnings of $3.00 per share, exceeding the analyst consensus estimate of $2.65.
Revenue reached $3.05 billion, compared with market expectations of $2.91 billion.
However, reported profitability was affected by a $450 million pre-tax charge associated with the settlement of the class-action lawsuit known as In re: da Vinci Surgical Robot Antitrust Litigation.
Following the charge, net income calculated under generally accepted accounting principles (GAAP) totalled $523 million, equivalent to $1.49 per diluted share, compared with $1.95 per diluted share in the corresponding period a year earlier.
The difference between adjusted and reported earnings reflected the impact of the legal settlement on the company’s quarterly financial results.
Why Are Changes to Instrument Pricing Receiving Attention?
Alongside the earnings figures, Intuitive Surgical provided further details about planned pricing adjustments affecting instruments and accessories used with its da Vinci robotic surgical systems.
Chief Executive Officer David Rosa and Chief Financial Officer Jamie Samath confirmed that the changes are expected to reduce da Vinci instrument and accessory revenue per procedure by approximately 3% to 5% on a constant-mix basis once fully implemented.
The adjustments are relevant because instruments and accessories generate recurring revenue as hospitals and surgical centres perform procedures using the company’s installed robotic systems.
Lower revenue per procedure could affect growth in this business segment, although the overall financial impact will also depend on procedure volumes, product mix and operating costs.
Management’s pricing plans have therefore become a focus for investors assessing the company’s revenue and profitability outlook heading into 2027.
How Did da Vinci Procedure Volumes Perform?
Intuitive Surgical reported a 10% year-on-year increase in US da Vinci procedures during the third quarter.
The domestic growth rate was among the company’s lowest readings in recent years, according to the supplied report.
International da Vinci procedure volumes increased by 20% over the same period, indicating a faster rate of growth outside the United States.
The difference between domestic and international procedure trends is relevant to the company’s outlook because procedure volumes influence demand for instruments and accessories.
Investors will be monitoring whether higher procedure volumes can offset the reduction in revenue per procedure resulting from the pricing adjustments.
What Are Wall Street Analysts Saying About Intuitive Surgical?
Several investment banks maintained positive ratings on Intuitive Surgical following the earnings announcement, despite acknowledging the potential effects of the company’s pricing changes.
JPMorgan raised its price target to $475 and maintained an Overweight rating.
Raymond James reduced its price target to $480 while retaining an Outperform rating.
Barclays increased its price target to $500 and reiterated its Overweight recommendation.
The analysts identified the possibility that lower instrument pricing could support additional procedure demand over time, potentially offsetting some of the reduction in revenue generated per procedure.
However, the extent of any resulting increase in surgical volumes remains uncertain, and the banks’ price targets represent their respective assessments rather than forecasts of guaranteed share price performance.
Is the Broader Stock Market Behind the Decline?
Intuitive Surgical’s pre-market decline occurred despite gains in major US equity indices.
The S&P 500 was approximately 0.2% higher, while the Nasdaq advanced 0.8%, indicating that the company’s shares were moving in the opposite direction to the broader market.
The timing of the decline suggests that the earnings announcement, legal settlement and pricing outlook were important factors in the share price movement.
Intuitive Surgical shares had already declined from their 52-week high of $603.88 before the latest results.
At the pre-market price of $404.99, the stock remained above its 52-week low of $328.57.
What Should Investors Watch Next?
The principal issue for Intuitive Surgical is how the planned instrument and accessory pricing reductions will affect recurring revenue as the changes are implemented.
Future quarterly results will provide further information on whether procedure growth, particularly in international markets, can compensate for lower revenue per procedure.
Investors will also be assessing the company’s operating margins and reported profitability following the third-quarter legal settlement charge.
Although Intuitive Surgical exceeded expectations for adjusted earnings and revenue, the combination of the settlement expense, pricing adjustments and slower US procedure growth provided additional information for investors evaluating the company’s financial outlook.
Intuitive Surgical stock price